Cutting Edge: Molecular Analysis of the Negative Regulatory Function of Lymphocyte Activation Gene-3

CD28/B7 SYSTEM OF T CELL COSTIMULATION

Lenschow, D. J., Walunas, T. L., & Bluestone, J. A. (1996) · Annual Review of Immunology · doi:10.1146/annurev.immunol.14.1.233 · Cited by 2,717 · see citing works

LAG-3, a novel lymphocyte activation gene closely related to CD4.

Triebel, F., Jitsukawa, S., Baixerás, E., Roman‐Roman, S., Genevée, C., Viégas-Pèquignot, E., & Hercend, T. (1990) · The Journal of Experimental Medicine · doi:10.1084/jem.171.5.1393 · Cited by 917 · see citing works

Characterization of the lymphocyte activation gene 3-encoded protein. A new ligand for human leukocyte antigen class II antigens.

Baixerás, E., Huard, B., Miossec, C., Jitsukawa, S., Martin, M., Hercend, T., Auffray, C., Triebel, F., & Piatier‐Tonneau, D. (1992) · The Journal of Experimental Medicine · doi:10.1084/jem.176.2.327 · Cited by 397 · see citing works

CD4/major histocompatibility complex class II interaction analyzed with CD4‐ and lymphocyte activation gene‐3 (LAG‐3)‐Ig fusion proteins

Huard, B., Prigent, P., Tournier, M., Bruniquel, D., & Triebel, F. (1995) · European Journal of Immunology · doi:10.1002/eji.1830250949 · Cited by 391 · see citing works

Cloning and expression of a cDNA coding for the human platelet-derived growth factor receptor: evidence for more than one receptor class.

Gronwald, R. G., Grant, F. J., Haldeman, B. A., Hart, C. E., O’Hara, P. J., Hagen, F. S., Ross, R., Bowen‐Pope, D. F., & Murray, M. J. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.10.3435 · Cited by 316 · see citing works

Characterization of the major histocompatibility complex class II binding site on LAG-3 protein

Huard, B., Mastrangeli, R., Prigent, P., Bruniquel, D., Donini, S., Tayar, N. E., Maigret, B., Dréano, M., & Triebel, F. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.11.5744 · Cited by 308 · see citing works

"Tolerosomes" are produced by intestinal epithelial cells

Karlsson, M., Lundin, S. B., Dahlgren, U. I., Kahu, H., Pettersson, I., & Telemo, E. (2001) · European Journal of Immunology · doi:10.1002/1521-4141(2001010)31:10 · Cited by 303 · see citing works

CD3/TCR complex‐associated lymphocyte activation gene‐3 molecules inhibit CD3/TCR signaling

Hannier, S., Tournier, M., Bismuth, G., & Triebel, F. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.161.8.4058 · Cited by 248 · see citing works

Retroviral-Mediated Transfer of the Green Fluorescent Protein Gene Into Murine Hematopoietic Cells Facilitates Scoring and Selection of Transduced Progenitors In Vitro and Identification of Genetically Modified Cells In Vivo

Persons, D. A., Allay, J. A., Allay, E. R., Smeyne, R. J., Ashmun, R. A., Sorrentino, B. P., & Nienhuis, A. W. (1997) · Blood · doi:10.1182/blood.v90.5.1777 · Cited by 222 · see citing works

Cellular expression and tissue distribution of the human LAG-3-encoded protein, an MHC class II ligand

Huard, B., Gaulard, P., Faure, F., Hercend, T., & Triebel, F. (1994) · Immunogenetics · doi:10.1007/bf00241263 · Cited by 202 · see citing works

T Cell Receptor Recognition of MHC Class II–Bound Peptide Flanking Residues Enhances Immunogenicity and Results in Altered TCR V Region Usage

Carson, R. T., Vignali, K. M., Woodland, D. L., & Vignali, D. A. A. (1997) · Immunity · doi:10.1016/s1074-7613(00)80360-x · Cited by 175 · see citing works

Independent Modes of Natural Killing Distinguished in Mice Lacking Lag3

Miyazaki, T., Dierich, A., Benoist, C. O., & Mathis, D. J. (1996) · Science · doi:10.1126/science.272.5260.405 · Cited by 173 · see citing works

T cell major histocompatibility complex class II molecules down‐regulate CD4+ T cell clone responses following LAG‐3 binding

Huard, B., Prigent, P., Pagès, F., Bruniquel, D., & Triebel, F. (1996) · European Journal of Immunology · doi:10.1002/eji.1830260533 · Cited by 132 · see citing works

The Majority of Immunogenic Epitopes Generate CD4+ T Cells That Are Dependent on MHC Class II-Bound Peptide-Flanking Residues

Arnold, P. Y., Gruta, N. L. L., Miller, T. J., Vignali, K. M., Adams, P. S., Woodland, D. L., & Vignali, D. A. A. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.169.2.739 · Cited by 121 · see citing works

Amino acid residues that flank core peptide epitopes and the extracellular domains of CD4 modulate differential signaling through the T cell receptor.

Vignali, D. A. A., & Strominger, J. L. (1994) · The Journal of Experimental Medicine · doi:10.1084/jem.179.6.1945 · Cited by 103 · see citing works

Direct evidence that a class II molecule and a simple globular protein generate multiple determinants.

Allen, P. M., McKEAN, D. J., Beck, B. N., Sheffield, J. B., & Glimcher, L. H. (1985) · The Journal of Experimental Medicine · doi:10.1084/jem.162.4.1264 · Cited by 82 · see citing works

An Improved Method for Generating Retroviral Producer Clones for Vectors Lacking a Selectable Marker Gene

Persons, D. A., Mehaffey, M. G., Kaleko, M., Nienhuis, A. W., & Vanin, E. F. (1998) · Blood Cells Molecules and Diseases · doi:10.1006/bcmd.1998.0184 · Cited by 81 · see citing works

LckBP1, a proline‐rich protein expressed in haematopoietic lineage cells, directly associates with the SH3 domain of protein tyrosine kinase p56lck.

Takemoto, Y., Furuta, M., Li, X., Strong-Sparks, W. J., & Hashimoto, Y. (1995) · The EMBO Journal · doi:10.1002/j.1460-2075.1995.tb07346.x · Cited by 79 · see citing works

The MHC class II ligand lymphocyte activation gene-3 is co-distributed with CD8 and CD3–TCR molecules after their engagement by mAb or peptide–MHC class I complexes

Hannier, S., & Triebel, F. (1999) · International Immunology · doi:10.1093/intimm/11.11.1745 · Cited by 72 · see citing works

Mouse CD4 binds MHC class II with extremely low affinity

Weber, S., & Karjalainen, K. (1993) · International Immunology · doi:10.1093/intimm/5.6.695 · Cited by 63 · see citing works

Profound Enhancement of T Cell Activation Mediated by the Interaction Between the TCR and the D3 Domain of CD4

Vignali, D. A. A., & Vignali, K. M. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.162.3.1431 · Cited by 53 · see citing works

Genomic organization of the human LAG-3/CD4 locus

Bruniquel, D., Borie, N., & Triebel, F. (1997) · Immunogenetics · doi:10.1007/s002510050332 · Cited by 47 · see citing works

Cloning of Murine LAG-3 by Magnetic Bead Bound Homologous Probes and PCR (GENE-CAPTURE PCR)

Mastrangeli, R., Micangeli, E., & Donini, S. (1996) · Analytical Biochemistry · doi:10.1006/abio.1996.0382 · Cited by 43 · see citing works

Identification of a protein, SPY75, with repetitive helix-turn-helix motifs and an SH3 domain as a major substrate for protein tyrosine kinase(s) activated by Fc epsilon RI cross-linking.

Fukamachi, H., Yamada, N., Miura, T., Kato, T., Ishikawa, M., Gulbins, E., Altman, A., Kawakami, Y., & Kawakami, T. (1994) · The Journal of Immunology · doi:10.4049/jimmunol.152.2.642 · Cited by 42 · see citing works

Reliable generation and use of MHC class II:γ2aFc multimers for the identification of antigen-specific CD4+ T cells

Arnold, P. Y., Vignali, K. M., Miller, T. B., Gruta, N. L. L., Cauley, L. S., Haynes, L., Adams, P. S., Swain, S. L., Woodland, D. L., & Vignali, D. A. A. (2002) · Journal of Immunological Methods · doi:10.1016/s0022-1759(02)00343-5 · Cited by 28 · see citing works

Phenotypic analysis of the murine CD4-related glycoprotein, CD223 (LAG-3)

(2002) · doi:10.1002/1521-4141(200208)32:8

Fundamental Mechanisms of Immune Checkpoint Blockade Therapy

Wei, S. C., Duffy, C. R., & Allison, J. P. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0367 · Cited by 3,088 · see citing works

Molecular Signature of CD8+ T Cell Exhaustion during Chronic Viral Infection

Wherry, E. J., Ha, S.-J., Kaech, S. M., Haining, W. N., Sarkar, S., Kalia, V., Subramaniam, S., Blattman, J. N., Barber, D. L., & Ahmed, R. (2007) · Immunity · doi:10.1016/j.immuni.2007.09.006 · Cited by 2,103 · see citing works

Lag-3, Tim-3, and TIGIT: co-inhibitory receptors with specialized functions in immune regulation

Anderson, A. C., Joller, N., & Kuchroo, V. K. (2016) · Immunity · doi:10.1016/j.immuni.2016.05.001 · Cited by 2,096 · see citing works

CD8 T Cell Exhaustion During Chronic Viral Infection and Cancer

McLane, L. M., Abdel-Hakeem, M. S., & Wherry, E. J. (2019) · Annual Review of Immunology · doi:10.1146/annurev-immunol-041015-055318 · Cited by 1,973 · see citing works

Immune Inhibitory Molecules LAG-3 and PD-1 Synergistically Regulate T-cell Function to Promote Tumoral Immune Escape

Woo, S.-R., Turnis, M. E., Goldberg, M. V., Bankoti, J., Selby, M., Nirschl, C. J., Bettini, M. L., Gravano, D. M., Vogel, P., Liu, C. L., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-1620 · Cited by 1,647 · see citing works

Immune checkpoint signaling and cancer immunotherapy

He, X., & Xu, C. (2020) · Cell Research · doi:10.1038/s41422-020-0343-4 · Cited by 1,384 · see citing works

Role of LAG-3 in Regulatory T Cells

Huang, C.-T., Workman, C. J., Flies, D., Pan, X., Marson, A. L., Zhou, G., Hipkiss, E. L., Ravi, S., Kowalski, J., Levitsky, H. I., et al. (2004) · Immunity · doi:10.1016/j.immuni.2004.08.010 · Cited by 1,325 · see citing works

Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4

Qin, S., Xu, L., Yi, M., Yu, S., Wu, K., & Luo, S. (2019) · Molecular Cancer · doi:10.1186/s12943-019-1091-2 · Cited by 1,145 · see citing works

LAG3 (CD223) as a Cancer Immunotherapy Target

Andrews, L. P., Marciscano, A., Drake, C., & Vignali, D. A. A. (2017) · Immunological Reviews · doi:10.1111/imr.12519 · Cited by 881 · see citing works

A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application

Okazaki, T., Chikuma, S., Iwai, Y., Fagarasan, S., & Honjo, T. (2013) · Nature Immunology · doi:10.1038/ni.2762 · Cited by 915 · see citing works

Coinhibitory Pathways in Immunotherapy for Cancer

Baumeister, S. H. C., Freeman, G. J., Dranoff, G., & Sharpe, A. H. (2016) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032414-112049 · Cited by 912 · see citing works

Fibrinogen-like Protein 1 Is a Major Immune Inhibitory Ligand of LAG-3

Wang, J., Sanmamed, M. F., Datar, I. J., Su, T. T., Ji, L., Sun, J., Chen, L., Chen, Y., Zhu, G., Yin, W., et al. (2018) · Cell · doi:10.1016/j.cell.2018.11.010 · Cited by 879 · see citing works

Next generation of immune checkpoint therapy in cancer: new developments and challenges

Marin-Acevedo, J. A., Dholaria, B., Soyano, A. E., Knutson, K. L., Chumsri, S., & Lou, Y. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0582-8 · Cited by 802 · see citing works

Regulatory T Cells Inhibit Dendritic Cells by Lymphocyte Activation Gene-3 Engagement of MHC Class II

Liang, B., Workman, C., Lee, J., Chew, C., Dale, B. M., Colonna, L., Flores, M., Li, N., Schweighoffer, E., Greenberg, S., et al. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.9.5916 · Cited by 566 · see citing works

LAG-3 regulates CD8+ T cell accumulation and effector function in murine self- and tumor-tolerance systems.

Grosso, J., Kelleher, C. C., Harris, T., Maris, C. H., Hipkiss, E. L., Marzo, A. D. D., Anders, R., Netto, G., Getnet, D., Bruno, T., et al. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31184 · Cited by 531 · see citing works

Inhibitory receptors and ligands beyond PD-1, PD-L1 and CTLA-4: breakthroughs or backups

Andrews, L. P., Yano, H., & Vignali, D. A. A. (2019) · Nature Immunology · doi:10.1038/s41590-019-0512-0 · Cited by 547 · see citing works

Cancer immunotherapies: advances and bottlenecks

Rui, R., Zhou, L., & He, S. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1212476 · Cited by 484 · see citing works

LAG-3: from molecular functions to clinical applications

Maruhashi, T., Sugiura, D., Okazaki, I., & Okazaki, T. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001014 · Cited by 462 · see citing works

T Cell Exhaustion

Baessler, A., & Vignali, D. A. A. (2024) · Annual Review of Immunology · doi:10.1146/annurev-immunol-090222-110914 · Cited by 420 · see citing works

Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy

Cai, L., Li, Y., Tan, J., Xu, L., & Li, Y. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01499-1 · Cited by 404 · see citing works

The promising immune checkpoint LAG-3: from tumor microenvironment to cancer immunotherapy

Long, L., Zhang, X., Chen, F., Pan, Q., Phiphatwatchara, P., Zeng, Y., & Chen, H. (2018) · Genes & Cancer · doi:10.18632/genesandcancer.180 · Cited by 386 · see citing works

Lymphocyte-activation gene 3 (LAG3): The next immune checkpoint receptor

Ruffo, E., Wu, R. C., Bruno, T. C., Workman, C. J., & Vignali, D. A. A. (2019) · Seminars in Immunology · doi:10.1016/j.smim.2019.101305 · Cited by 381 · see citing works

NK Cell-Based Immune Checkpoint Inhibition

Khan, M. B., Arooj, S., & Wang, H. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00167 · Cited by 359 · see citing works

Lymphocyte Activation Gene-3 (CD223) Regulates the Size of the Expanding T Cell Population Following Antigen Activation In Vivo

Workman, C. J., Cauley, L. S., Kim, I.-J., Blackman, M. A., Woodland, D. L., & Vignali, D. A. A. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.9.5450 · Cited by 351 · see citing works

LAG-3 as the third checkpoint inhibitor

Aggarwal, V., Workman, C. J., & Vignali, D. A. A. (2023) · Nature Immunology · doi:10.1038/s41590-023-01569-z · Cited by 344 · see citing works

Immunotherapy for glioblastoma: current state, challenges, and future perspectives

Liu, Y., Fei, Z., Ali, H. A., Lathia, J. D., & Chen, P. (2024) · Cellular and Molecular Immunology · doi:10.1038/s41423-024-01226-x · Cited by 367 · see citing works

LAG-3 in Cancer Immunotherapy

Goldberg, M. V., & Drake, C. G. (2010) · Current topics in microbiology and immunology · doi:10.1007/82_2010_114 · Cited by 337 · see citing works

Negative Regulation of T Cell Homeostasis by Lymphocyte Activation Gene-3 (CD223)

Workman, C. J., & Vignali, D. A. A. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.2.688 · Cited by 333 · see citing works

PD-1 and LAG-3 inhibitory co-receptors act synergistically to prevent autoimmunity in mice

Okazaki, T., Okazaki, I., Wang, J., Sugiura, D., Nakaki, F., Yoshida, T., Kato, Y., Fagarasan, S., Muramatsu, M., Eto, T., et al. (2011) · The Journal of Experimental Medicine · doi:10.1084/jem.20100466 · Cited by 328 · see citing works

Potential role of glutathione in evolution of thiol-based redox signaling sites in proteins

Mohanasundaram, K. A., Haworth, N. L., Grover, M. P., Crowley, T. M., Goscinski, A. M., & Wouters, M. A. (2015) · Frontiers in Pharmacology · doi:10.3389/fphar.2015.00001 · Cited by 326 · see citing works

The CD4‐related molecule, LAG‐3 (CD223), regulates the expansion of activated T cells

Workman, C. J., & Vignali, D. A. A. (2003) · European Journal of Immunology · doi:10.1002/eji.200323382 · Cited by 319 · see citing works

Tumor microenvironment signaling and therapeutics in cancer progression

Goenka, A., Khan, F., Verma, B., Sinha, P., Dmello, C. C., Jogalekar, M. P., Gangadaran, P., & Ahn, B. (2023) · Cancer Communications · doi:10.1002/cac2.12416 · Cited by 323 · see citing works

LAG-3 Regulates Plasmacytoid Dendritic Cell Homeostasis

Workman, C. J., Wang, Y., Kasmi, K. C. E., Pardoll, D. M., Murray, P. J., Drake, C. G., & Vignali, D. A. A. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0800185 · Cited by 316 · see citing works

LAG3 and PD1 co-inhibitory molecules collaborate to limit CD8+ T cell signaling and dampen antitumor immunity in a murine ovarian cancer model

Huang, R.-Y., Eppolito, C., Lele, S., Shrikant, P. A., Matsuzaki, J., & Odunsi, K. O. (2015) · Oncotarget · doi:10.18632/oncotarget.4751 · Cited by 309 · see citing works

Co-stimulatory and Co-inhibitory Pathways in Autoimmunity

Zhang, Q., & Vignali, D. A. A. (2016) · Immunity · doi:10.1016/j.immuni.2016.04.017 · Cited by 299 · see citing works

Costimulatory and coinhibitory receptors in anti‐tumor immunity

Driessens, G., Kline, J. P., & Gajewski, T. F. (2009) · Immunological Reviews · doi:10.1111/j.1600-065x.2009.00771.x · Cited by 284 · see citing works

Metalloproteases regulate T‐cell proliferation and effector function via LAG‐3

Li, N., Wang, Y., Forbes, K., Vignali, K. M., Heale, B. S. E., Säftig, P., Hartmann, D., Black, R. A., Rossi, J. J., Blobel, C., et al. (2007) · The EMBO Journal · doi:10.1038/sj.emboj.7601520 · Cited by 282 · see citing works

LAG-3 inhibits the activation of CD4+ T cells that recognize stable pMHCII through its conformation-dependent recognition of pMHCII

Maruhashi, T., Okazaki, I.-M., Sugiura, D., Takahashi, S., Maeda, T. K., Shimizu, K., & Okazaki, T. (2018) · Nature Immunology · doi:10.1038/s41590-018-0217-9 · Cited by 275 · see citing works

Expression of lymphocyte activation gene 3 (LAG-3) on B cells is induced by T cells

Kisielow, M., Kisielow, J., Sollami, G., & Karjalainen, K. (2005) · European Journal of Immunology · doi:10.1002/eji.200526090 · Cited by 271 · see citing works

LAG-3, TIM-3, and TIGIT: Distinct functions in immune regulation

Joller, N., Anderson, A. C., & Kuchroo, V. K. (2024) · Immunity · doi:10.1016/j.immuni.2024.01.010 · Cited by 287 · see citing works

Immune checkpoints in the tumor microenvironment

Toor, S. M., Nair, V. S., Decock, J. V., & Elkord, E. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.06.021 · Cited by 238 · see citing works

CRISPR-Cas9 mediated LAG-3 disruption in CAR-T cells

Zhang, Y., Zhang, X., Cheng, C., Mu, W., Liu, X., Li, N., Wei, X., Liu, X., Xia, C., & Wang, H. (2017) · Frontiers of Medicine · doi:10.1007/s11684-017-0543-6 · Cited by 239 · see citing works

Checkpoint inhibitors in pancreatic cancer

Henriksen, A., Dyhl-Polk, A., Chen, I. M., & Nielsen, D. L. (2019) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2019.06.005 · Cited by 217 · see citing works

Understanding LAG-3 Signaling

Chocarro, L., Blanco, E., Zuazo, M., Arasanz, H., Bocanegra, A., Fernández, L., Morente, P., Fernández-Hinojal, G., Echaide, M., Garnica, M., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22105282 · Cited by 217 · see citing works

LAG3 associates with TCR–CD3 complexes and suppresses signaling by driving co-receptor–Lck dissociation

Guy, C. S., Mitrea, D. M., Chou, P.-C., Temirov, J. P., Vignali, K. M., Liu, X., Zhang, H., Kriwacki, R. W., Bruchez, M. P., Watkins, S. C., et al. (2022) · Nature Immunology · doi:10.1038/s41590-022-01176-4 · Cited by 214 · see citing works

Negative regulators of T‐cell activation: potential targets for therapeutic intervention in cancer, autoimmune disease, and persistent infections

Pentcheva‐Hoang, T., Corse, E., & Allison, J. P. (2009) · Immunological Reviews · doi:10.1111/j.1600-065x.2009.00763.x · Cited by 202 · see citing works

T cell exhaustion: from pathophysiological basics to tumor immunotherapy

Catakovic, K., Klieser, E., Neureiter, D., & Geisberger, R. (2017) · Cell Communication and Signaling · doi:10.1186/s12964-016-0160-z · Cited by 202 · see citing works

In vivo CRISPR screening in CD8 T cells with AAV–Sleeping Beauty hybrid vectors identifies membrane targets for improving immunotherapy for glioblastoma

Ye, L., Park, J. J.-Y., Dong, M. B., Yang, Q., Chow, R. D.-W., Peng, L., Du, Y., Guo, J., Dai, X., Wang, G., et al. (2019) · Nature Biotechnology · doi:10.1038/s41587-019-0246-4 · Cited by 199 · see citing works

Beyond CTLA-4 and PD-1, the Generation Z of Negative Checkpoint Regulators

Mercier, I. L., Lines, J. L., & Noelle, R. J. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00418 · Cited by 196 · see citing works

The negative regulatory function of the lymphocyte‐activation gene‐3 co‐receptor (CD223) on human T cells

Maçon‐Lemaître, L., & Triebel, F. (2005) · Immunology · doi:10.1111/j.1365-2567.2005.02145.x · Cited by 192 · see citing works

Comparative transcriptomics of extreme phenotypes of human HIV-1 infection and SIV infection in sooty mangabey and rhesus macaque

Rotger, M., Dalmau, J., Rauch, A., McLaren, P. J., Bosinger, S. E., Martínez, R., Utay, N. S., Roque, A., Liebner, J. C., Battegay, M., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci45235 · Cited by 188 · see citing works

Immune Checkpoint LAG3 and Its Ligand FGL1 in Cancer

Shi, A., Tang, X., Xiong, Y., Zheng, K., Liu, Y., Shi, X.-G., Lv, Y., Jiang, T., Ma, N., & Zhao, J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2021.785091 · Cited by 186 · see citing works

Immune checkpoint inhibitors: Key trials and an emerging role in breast cancer

Gaynor, N., Crown, J. P., & Collins, D. M. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.06.016 · Cited by 184 · see citing works

LAG3’s Enigmatic Mechanism of Action

Graydon, C. G., Mohideen, S., & Fowke, K. R. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.615317 · Cited by 183 · see citing works

Immune checkpoint molecules in natural killer cells as potential targets for cancer immunotherapy

Cao, Y., Wang, X., Jin, T., Tian, Y., Dai, C., Widarma, C., Song, R., & Xu, F. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00348-8 · Cited by 184 · see citing works

Lymphocyte Activation Gene 3 (LAG-3) Modulates the Ability of CD4 T-cells to Be Suppressed In Vivo

Durham, N. M., Nirschl, C. J., Jackson, C. M., Elias, J., Kochel, C. M., Anders, R. A., & Drake, C. G. (2014) · PLoS ONE · doi:10.1371/journal.pone.0109080 · Cited by 178 · see citing works

The promising immune checkpoint LAG‐3 in cancer immunotherapy: from basic research to clinical application

Huo, J.-L., Wang, Y.-T., Fu, W.-J., Lu, N., & Liu, Z.-S. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.956090 · Cited by 176 · see citing works

Basic Overview of Current Immunotherapy Approaches in Cancer

Velcheti, V., & Schalper, K. A. (2016) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_156572 · Cited by 176 · see citing works

Signaling pathways and targeted therapies in lung squamous cell carcinoma: mechanisms and clinical trials

Niu, Z., Jin, R., Zhang, Y., & Li, H. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01200-x · Cited by 172 · see citing works

Cutting Edge: Accelerated Autoimmune Diabetes in the Absence of LAG-3

Bettini, M., Szymczak-Workman, A. L., Forbes, K., Castellaw, A. H., Selby, M., Pan, X., Drake, C. G., Korman, A. J., & Vignali, D. A. A. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1100714 · Cited by 170 · see citing works

Immune checkpoint proteins: Signaling mechanisms and molecular interactions in cancer immunotherapy

Gaikwad, S. R., Agrawal, M. Y., Kaushik, I., Ramachandran, S., & Srivastava, S. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.03.014 · Cited by 153 · see citing works

Inhibitory receptors as targets for cancer immunotherapy

Turnis, M. E., Andrews, L. P., & Vignali, D. A. A. (2015) · European Journal of Immunology · doi:10.1002/eji.201344413 · Cited by 154 · see citing works

LAG-3: a regulator of T-cell and DC responses and its use in therapeutic vaccination

Triebel, F. (2003) · Trends in Immunology · doi:10.1016/j.it.2003.10.001 · Cited by 150 · see citing works

Not All Immune Checkpoints Are Created Equal

Linhares, A. D. S., Leitner, J. M., Grabmeier‐Pfistershammer, K., & Steinberger, P. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01909 · Cited by 147 · see citing works

The Upregulation of LAG-3 on T Cells Defines a Subpopulation with Functional Exhaustion and Correlates with Disease Progression in HIV-Infected Subjects

Tian, X., Zhang, A., Qiu, C., Wang, W., Yang, Y. Z., Qiu, C., Liu, A., Zhu, L., Yuan, S., Hu, H., et al. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1402176 · Cited by 145 · see citing works

Biochemical Analysis of the Regulatory T Cell Protein Lymphocyte Activation Gene-3 (LAG-3; CD223)

Li, N., Workman, C. J., Martin, S., & Vignali, D. A. A. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.11.6806 · Cited by 139 · see citing works

Expression of LAG-3 is coincident with the impaired effector function of HBV-specific CD8+ T cell in HCC patients

Li, F., Zhang, Y., Jin, G., Yao, L., & Wu, D. (2012) · Immunology Letters · doi:10.1016/j.imlet.2012.12.004 · Cited by 138 · see citing works

Evolution of the CD4 Family: Teleost Fish Possess Two Divergent Forms of CD4 in Addition to Lymphocyte Activation Gene-3

Laing, K. J., Zou, J., Purcell, M. K., Phillips, R., Secombes, C. J., & Hansen, J. D. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.6.3939 · Cited by 137 · see citing works

Checkpoint inhibitors in hematological malignancies

Ok, C. Y., & Young, K. H. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0474-3 · Cited by 136 · see citing works

Tim-3, Lag-3, and TIGIT

Joller, N., & Kuchroo, V. K. (2017) · Current topics in microbiology and immunology · doi:10.1007/82_2017_62 · Cited by 138 · see citing works

Molecular Pathways and Mechanisms of LAG3 in Cancer Therapy

Andrews, L. P., Cillo, A. R., Karapetyan, L., Kirkwood, J. M., Workman, C. J., & Vignali, D. A. A. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-2390 · Cited by 122 · see citing works

LAG3 (LAG-3, CD223) DNA methylation correlates with LAG3 expression by tumor and immune cells, immune cell infiltration, and overall survival in clear cell renal cell carcinoma

Klümper, N., Ralser, D. J., Bawden, E., Landsberg, J., Zarbl, R., Kristiansen, G., Toma, M. I., Ritter, M., Hölzel, M., Ellinger, J., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000552 · Cited by 116 · see citing works

IELs: enforcing law and order in the court of the intestinal epithelium

Cheroutre, H. (2005) · Immunological Reviews · doi:10.1111/j.0105-2896.2005.00284.x · Cited by 117 · see citing works

The CD4-like molecule LAG-3, biology and therapeutic applications

Sierro, S. R., Romero, P. J., & Speiser, D. E. (2010) · Expert Opinion on Therapeutic Targets · doi:10.1517/14712598.2011.540563 · Cited by 115 · see citing works

Atypical motifs in the cytoplasmic region of the inhibitory immune co-receptor LAG-3 inhibit T cell activation

Maeda, T. K., Sugiura, D., Okazaki, I., Maruhashi, T., & Okazaki, T. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.ra119.007455 · Cited by 115 · see citing works

Targeting Checkpoint Receptors and Molecules for Therapeutic Modulation of Natural Killer Cells

Kim, N., & Kim, H. S. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02041 · Cited by 110 · see citing works

Trafficking of LAG-3 to the Surface on Activated T Cells via Its Cytoplasmic Domain and Protein Kinase C Signaling

Bae, J., Lee, S. J., Park, C., Lee, Y. S., & Chun, T. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1401025 · Cited by 106 · see citing works

The Confounders of Cancer Immunotherapy: Roles of Lifestyle, Metabolic Disorders and Sociological Factors

Deshpande, R. P., Sharma, S., & Watabe, K. (2020) · Cancers · doi:10.3390/cancers12102983 · Cited by 101 · see citing works

PD-L1/LAG-3 bispecific antibody enhances tumor-specific immunity

Jiang, H., Ni, H., Zhang, P., Guo, X., Wu, M., Shen, H., Wang, J., Wu, W., Wu, Z., Ding, J., et al. (2021) · OncoImmunology · doi:10.1080/2162402x.2021.1943180 · Cited by 99 · see citing works

Clinical landscape of LAG-3-targeted therapy

Chocarro, L., Blanco, E., Arasanz, H., Fernández, L., Bocanegra, A., Echaide, M., Garnica, M., Ramos, P., Fernández-Hinojal, G., Vera, R., et al. (2022) · Immuno-Oncology Technology · doi:10.1016/j.iotech.2022.100079 · Cited by 98 · see citing works

Newly Emerging Immune Checkpoints: Promises for Future Cancer Therapy

Torphy, R. J., Schulick, R. D., & Zhu, Y. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18122642 · Cited by 98 · see citing works

CD8 + T cell exhaustion in anti‐tumour immunity: The new insights for cancer immunotherapy

Huang, Y., Jia, A., Wang, Y., & Liu, G. (2022) · Immunology · doi:10.1111/imm.13588 · Cited by 95 · see citing works

Targeting the NF-κB pathway as a potential regulator of immune checkpoints in cancer immunotherapy

Ebrahimi, N., Abdulwahid, A. R. R., Mansouri, A., Karimi, N., Bostani, R. J., Beiranvand, S., Adelian, S., Khorram, R., Vafadar, R., Hamblin, M. R., et al. (2024) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-023-05098-8 · Cited by 98 · see citing works

Negative immune checkpoints on T lymphocytes and their relevance to cancer immunotherapy

Śledzińska, A., Menger, L., Bergerhoff, K. F., Peggs, K. S., & Quezada, S. A. (2015) · Molecular Oncology · doi:10.1016/j.molonc.2015.10.008 · Cited by 93 · see citing works

LAG3 ectodomain structure reveals functional interfaces for ligand and antibody recognition

Ming, Q., Celias, D. P., Wu, C., Cole, A. R., Singh, S., Mason, C. C., Dong, S., Tran, T. H., Amarasinghe, G. K., Ruffell, B., et al. (2022) · Nature Immunology · doi:10.1038/s41590-022-01238-7 · Cited by 92 · see citing works

Immune checkpoint molecules in pregnancy: Focus on regulatory T cells

Zhang, Y., & Sun, H. (2020) · European Journal of Immunology · doi:10.1002/eji.201948382 · Cited by 91 · see citing works

Human Dendritic Cells Acquire a Semimature Phenotype and Lymph Node Homing Potential through Interaction with CD4+CD25+ Regulatory T Cells

Bayry, J., Triebel, F., Kaveri, S. V., & Tough, D. F. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.7.4184 · Cited by 91 · see citing works

Pancreatic Cancer Signaling Pathways, Genetic Alterations, and Tumor Microenvironment: The Barriers Affecting the Method of Treatment

Javadrashid, D., Baghbanzadeh, A., Derakhshani, A., Leone, P., Silvestris, N., Racanelli, V., Solimando, A. G., & Baradaran, B. (2021) · Biomedicines · doi:10.3390/biomedicines9040373 · Cited by 87 · see citing works

Tumor Immunology and Immunotherapy of Non-Small-Cell Lung CancerPreprint

Cascone, T., Fradette, J. J., Pradhan, M., & Gibbons, D. L. (2021) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a037895 · Cited by 85 · see citing works

Differential subcellular localization of the regulatory T‐cell protein LAG‐3 and the coreceptor CD4

Woo, S., Li, N., Bruno, T. C., Forbes, K., Brown, S. A., Workman, C. J., Drake, C. G., & Vignali, D. A. A. (2010) · European Journal of Immunology · doi:10.1002/eji.200939874 · Cited by 83 · see citing works

Mechanisms of Action of Regulatory T Cells Specific for Paternal Antigens During Pregnancy

Schumacher, A., Wafula, P. O., Bertoja, A. Z., Sollwedel, A., Thuere, C., Wollenberg, I., Yagita∥, H., Volk, H., & Zenclussen, A. C. (2007) · Obstetrics and Gynecology · doi:10.1097/01.aog.0000284625.10175.31 · Cited by 79 · see citing works

Control of NK Cell Activation by Immune Checkpoint Molecules

Beldi‐Ferchiou, A., & Caillat‐Zucman, S. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18102129 · Cited by 77 · see citing works

Functional Genomic Analysis of the Response of HIV‐1–Infected Lymphatic Tissue to Antiretroviral Therapy

Li, Q., Schacker, T. W., Carlis, J. V., Beilman, G. J., Nguyen, P. L., & Haase, A. T. (2004) · The Journal of Infectious Diseases · doi:10.1086/381396 · Cited by 76 · see citing works

News on immune checkpoint inhibitors as immunotherapy strategies in adult and pediatric solid tumors

Melaiu, O., Lucarini, V., Giovannoni, R., Fruci, D., & Gemignani, F. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.07.001 · Cited by 75 · see citing works

Ligand-induced ubiquitination unleashes LAG3 immune checkpoint function by hindering membrane sequestration of signaling motifs

Jiang, Y., Dai, A., Huang, Y., Li, H., Cui, J., Yang, H., Si, L., Jiao, T., Ren, Z., Zhang, Z., et al. (2025) · Cell · doi:10.1016/j.cell.2025.02.014 · Cited by 74 · see citing works

Roles of LAG3 and EGR2 in regulatory T cells

Okamura, T., Fujio, K., Sumitomo, S., & Yamamoto, K. (2012) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2011-200588 · Cited by 74 · see citing works

Small Molecule Inhibition of GSK-3 Specifically Inhibits the Transcription of Inhibitory Co-receptor LAG-3 for Enhanced Anti-tumor Immunity

Rudd, C. E., Chanthong, K., & Taylor, A. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.01.076 · Cited by 72 · see citing works

Targeted Anti‐Tumor Immunotherapy Using Tumor Infiltrating Cells

Xie, Y., Xie, F., Zhang, L., Zhou, X., Huang, J., Wang, F., Jin, J., Zhang, L., Zeng, L., & Zhou, F. (2021) · Advanced Science · doi:10.1002/advs.202101672 · Cited by 71 · see citing works

Soluble Human LAG-3 Molecule Amplifies the In vitro Generation of Type 1 Tumor-Specific Immunity

Casati, C., Camisaschi, C., Rini, F., Arienti, F., Rivoltini, L., Triebel, F., Parmiani, G., & Castelli, C. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2728 · Cited by 72 · see citing works

Beyond PD-1/PD-L1 Inhibition: What the Future Holds for Breast Cancer Immunotherapy

Chrétien, S., Zerdes, I., Bergh, J. C. S., Matikas, A., & Foukakis, T. (2019) · Cancers · doi:10.3390/cancers11050628 · Cited by 70 · see citing works

The CD4‐related molecule, LAG‐3 (CD223), regulates the expansion of activated T cells

Workman, C. J., & Vignali, D. A. A. (2003) · European Journal of Immunology · doi:10.1002/eji.200323382 · Cited by 319 · see citing works

LAG-3: a regulator of T-cell and DC responses and its use in therapeutic vaccination

Triebel, F. (2003) · Trends in Immunology · doi:10.1016/j.it.2003.10.001 · Cited by 150 · see citing works

The negative regulatory function of the lymphocyte‐activation gene‐3 co‐receptor (CD223) on human T cells

Maçon‐Lemaître, L., & Triebel, F. (2005) · Immunology · doi:10.1111/j.1365-2567.2005.02145.x · Cited by 192 · see citing works

Negative Regulation of T Cell Homeostasis by Lymphocyte Activation Gene-3 (CD223)

Workman, C. J., & Vignali, D. A. A. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.2.688 · Cited by 333 · see citing works

Biochemical Analysis of the Regulatory T Cell Protein Lymphocyte Activation Gene-3 (LAG-3; CD223)

Li, N., Workman, C. J., Martin, S., & Vignali, D. A. A. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.11.6806 · Cited by 139 · see citing works